Who
Douglas G. Cole
Director
Company insider
Files Form 4 as: Director, Foghorn Therapeutics; Director, Sana Biotechnology; Director, Sigilon Therapeutics; Director, Denali Therapeutics; Director, Quanterix; Director, Editas Medicine; Director, Agios Pharmaceuticals; Director, Receptos.
In numbers
- Trades disclosed
- 116
- Buys
- 0
- Sells
- 29
- Bought
- $0
- Sold
- $7.9M
- Companies
- 10
- Companies where not an officer
- 10
- First trade
- 17 Mar 2010
- Last trade
- 24 Jun 2026
- Last filed
- 25 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 2 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 24 Jun 2026filed 25 Jun 2026 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $114K28,000 at $4.08 | filing |
| 17 Jun 2025filed 17 Jun 2025 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $120K25,000 at $4.79 | filing |
| 26 Jun 2024filed 28 Jun 2024 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | $88K16,000 at $5.52 | filing |
| 6 Jun 2024filed 15 Jul 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 6 Jun 2024filed 7 Jun 2024 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —54,278 at $0.00 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code D | $4,535683 at $6.64 | filing |
| 11 Aug 2023filed 11 Aug 2023 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code D | $3,415683 at $5.00 | filing |
| 21 Jun 2023filed 22 Jun 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 8 Jun 2023filed 9 Jun 2023 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,649 at $0.00 | filing |
| 1 Jun 2023filed 5 Jun 2023 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —4,216 at $0.00 | filing |
| 19 May 2023filed 22 May 2023 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code A | —8,888 at $0.00 | filing |
| 21 Jun 2022filed 22 Jun 2022 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —16,000 at $0.00 | filing |
| 6 Jun 2022filed 8 Jun 2022 | SANA Sana Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —65,000 at $0.00 | filing |
| 2 Jun 2022filed 6 Jun 2022 | DNLI Denali Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —17,959 at $0.00 | filing |
| 2 Jun 2022filed 6 Jun 2022 | DNLI Denali TherapeuticsBiotechnology | SEC FORM 4 Code A | —5,986 at $0.00 | filing |
| 26 May 2022filed 27 May 2022 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code A | —8,888 at $0.00 | filing |
| 13 Jul 2021filed 14 Jul 2021 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —12,530 at $0.00 | filing |
| 24 Jun 2021filed 28 Jun 2021 | Sigilon Therapeuticsoption or derivative | SEC FORM 4 Code A | $89K8,888 at $9.97 | filing |
News
No headline names them, or the companies they trade most, lately.